MX2023000899A - Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias. - Google Patents
Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias.Info
- Publication number
- MX2023000899A MX2023000899A MX2023000899A MX2023000899A MX2023000899A MX 2023000899 A MX2023000899 A MX 2023000899A MX 2023000899 A MX2023000899 A MX 2023000899A MX 2023000899 A MX2023000899 A MX 2023000899A MX 2023000899 A MX2023000899 A MX 2023000899A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- hydroxybutyrate
- beta
- prevention
- treatment
- Prior art date
Links
- 230000000241 respiratory effect Effects 0.000 title abstract 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000011084 recovery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En varias implementaciones, el beta-hidroxibutirato se puede administrar oralmente a individuos. La administración puede permitir el tratamiento y/o prevención de enfermedades respiratorias, en algunas implementaciones. La administración puede reducir los tiempos de recuperación y mejorar los resultados en los individuos con enfermedades respiratorias.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055798P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/043076 WO2022020781A1 (en) | 2020-07-23 | 2021-07-23 | Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses |
| US17/384,632 US11752119B2 (en) | 2020-07-23 | 2021-07-23 | Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000899A true MX2023000899A (es) | 2023-06-15 |
Family
ID=79689099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000899A MX2023000899A (es) | 2020-07-23 | 2021-07-23 | Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11752119B2 (es) |
| EP (1) | EP4185287A1 (es) |
| JP (1) | JP2023535067A (es) |
| CN (1) | CN116490181A (es) |
| AU (1) | AU2021311835A1 (es) |
| CA (1) | CA3189948A1 (es) |
| MX (1) | MX2023000899A (es) |
| WO (1) | WO2022020781A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024067584A1 (zh) * | 2022-09-27 | 2024-04-04 | 南京纽邦生物科技有限公司 | 3-羟基丁酸与3-羟基丁酸钠的复合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004108740A2 (en) | 2003-06-03 | 2004-12-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| WO2017184788A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| CA3118317A1 (en) | 2018-10-29 | 2020-05-07 | Keto Patent Group, Inc. | Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans |
-
2021
- 2021-07-23 MX MX2023000899A patent/MX2023000899A/es unknown
- 2021-07-23 US US17/384,632 patent/US11752119B2/en active Active
- 2021-07-23 CN CN202180064869.0A patent/CN116490181A/zh active Pending
- 2021-07-23 WO PCT/US2021/043076 patent/WO2022020781A1/en active Application Filing
- 2021-07-23 CA CA3189948A patent/CA3189948A1/en active Pending
- 2021-07-23 EP EP21846868.4A patent/EP4185287A1/en active Pending
- 2021-07-23 JP JP2023504584A patent/JP2023535067A/ja active Pending
- 2021-07-23 AU AU2021311835A patent/AU2021311835A1/en active Pending
-
2023
- 2023-07-27 US US18/227,210 patent/US20230364042A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4185287A1 (en) | 2023-05-31 |
| WO2022020781A1 (en) | 2022-01-27 |
| US11752119B2 (en) | 2023-09-12 |
| CA3189948A1 (en) | 2022-01-27 |
| CN116490181A (zh) | 2023-07-25 |
| JP2023535067A (ja) | 2023-08-15 |
| AU2021311835A1 (en) | 2023-03-09 |
| US20220023242A1 (en) | 2022-01-27 |
| US20230364042A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| MX2010002735A (es) | Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno. | |
| Smyth et al. | Treatment of locally recurrent mucosal melanoma with topical imiquimod | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2021002322A (es) | Nuevos metodos. | |
| WO2018089328A8 (en) | TREATMENT OF CNS DISEASES USING GCS STIMULATORS | |
| WO2018025080A3 (en) | Compositions for enhancing brain activity | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2018012800A (es) | Administracion de metabolitos de berberina. | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| SG10201900559VA (en) | Treatment and prevention of the common cold using povidone-iodine | |
| MX2023000899A (es) | Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias. | |
| UY26422A1 (es) | Método para administrar un inhibidor de fosfodiesterasa 4 | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| WO2019155360A3 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| EA200801890A1 (ru) | Средство для лечения шума в ушах | |
| BR112022000734A2 (pt) | Método para tratar câncer em um paciente, uso de composto 1, e, composto 1 | |
| GEP20227432B (en) | Therapy of high-risk human papillomavirus infections | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| Munthe-Kaas et al. | Effectiveness of Interventions to Reduce Homelessness: A Systematic Review [Internet] | |
| UA130168U (uk) | Спосіб комплексного лікування та профілактики пацієнтів з бронхіальною астмою на тлі надмірної маси тіла або ожиріння | |
| UA117396C2 (uk) | Спосіб еферентної терапії гострих кишкових інфекцій у дорослих хворих |